Back to Search
Start Over
Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis
- Source :
- PLoS Neglected Tropical Diseases, Vol 15, Iss 7, p e0009551 (2021), PLoS Neglected Tropical Diseases
- Publication Year :
- 2021
- Publisher :
- Public Library of Science (PLoS), 2021.
-
Abstract
- Background Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how this proportion varies with selected covariates. Methodology/Principal findings This systematic review and meta-analysis examined the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with selected covariates. Three models using the maximum likelihood method assessed these proportions by study group, covariates and individually extracted data (protocol CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled (95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5–86.9) using the titre cut off >1:20 and 83.9% (82.2–85.6), 70.2% (68.1–72.5) and 54.2% (52.0–56.5) with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0–89.2], >1:160, 74.4% [67.5–79.7]) than those with mild presentation (56.7% [49.9–62.9] and 44.1% [37.3–50.6], respectively) and lowest among asymptomatic infections (28.6% [17.9–39.2] and 10.0% [3.7–20.1], respectively). IgG and neutralising antibody levels correlated poorly. Conclusions/Significance 85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibodies. This proportion varied with disease severity, study setting, time since infection and the method used to measure antibodies.<br />Author summary Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) elicits adaptive immunological responses, including immunoglobulins A, M, and G and neutralising antibodies. Neutralising antibodies are considered markers of functional immunity and protection. However, not all individuals with proven infections have detectable neutralising antibodies. In this systematic review, we investigated the proportion of individuals with former SARS-CoV-2 infections who develop neutralising antibodies, whether their titres vary with disease severity, and their correlation with Immunoglobulin G. We found that approximately 85% of individuals with SARS-CoV-2 infection have detectable neutralising antibodies. This proportion was higher among patients with severe Coronavirus Disease 19 and lower in asymptomatic infections. The variation across studies reflected the wide range of methods used to measure both immunoglobulins and neutralising antibodies, and highlight the need for an international reference standard to measure SARS-CoV-2 antibodies.
- Subjects :
- RNA viruses
0301 basic medicine
Viral Diseases
Pulmonology
Physiology
Coronaviruses
RC955-962
Acute infection
Antibodies, Viral
Biochemistry
Gastroenterology
Medical Conditions
Mathematical and Statistical Techniques
Immune Physiology
Arctic medicine. Tropical medicine
Medicine and Health Sciences
Prevalence
wc_505
Case Series
Enzyme-Linked Immunoassays
Pathology and laboratory medicine
media_common
Immune System Proteins
biology
Convalescence
Statistics
Medical microbiology
Metaanalysis
w_20.5
Titer
Infectious Diseases
Research Design
Meta-analysis
Viruses
Physical Sciences
Acute Disease
qw_160
SARS CoV 2
Pathogens
medicine.symptom
Antibody
Public aspects of medicine
RA1-1270
Research Article
medicine.medical_specialty
SARS coronavirus
Patients
Coronavirus disease 2019 (COVID-19)
Clinical Research Design
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
media_common.quotation_subject
Immunology
030106 microbiology
Research and Analysis Methods
Microbiology
Asymptomatic
Antibodies
Respiratory Disorders
03 medical and health sciences
Internal medicine
medicine
Humans
Statistical Methods
Immunoassays
qw_575
Inpatients
SARS-CoV-2
business.industry
Organisms
Viral pathogens
Public Health, Environmental and Occupational Health
Biology and Life Sciences
Proteins
COVID-19
Covid 19
Antibodies, Neutralizing
Microbial pathogens
Health Care
030104 developmental biology
Respiratory Infections
Immunologic Techniques
biology.protein
business
Mathematics
Subjects
Details
- Language :
- English
- ISSN :
- 19352735 and 19352727
- Volume :
- 15
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- PLoS Neglected Tropical Diseases
- Accession number :
- edsair.doi.dedup.....120e4efd44952beaa77bfe64f0fa351d